Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: Results from the EPICOVIDEHA Registry

Authors

Tommaso Francesco Aiello, Universitat de Barcelona, Spain.
Jon Salmanton-Garcia, University of Cologne, Germany
Francesco Marchesi, IRCCS Regina Elena National Cancer Institute, Rome
Barbora Weinbergerova, Masaryk University Hospital Brno, Czech Republic
Andreas Glenthoj, Copenhagen University Hospital, Denmark
Jens Van Praet, AZ Sint-Jan Brugge AV, Belgium
Francesca Farina, IRCCS Ospedale San Raffaele, Italy
Julio Davila-Valls, Hospital Nuestra Senora de Sonsoles, Spain
Sonia Martin-Perez, Hospital Nuestra Senora de Sonsoles, Spain
Natasha Ali, Aga Khan UniversityFollow

Document Type

Letter to the Editor

Department

Pathology and Laboratory Medicine

Comments

Abstract, volume, issue and pagination are not provided by the author/publisher.

Publication (Name of Journal)

Haematologica

DOI

10.3324/haematol.2023.284678

Recommended Citation

Aiello, T. F., Salmanton-Garcia, J., Marchesi, F., Weinbergerova, B., Glenthoj, A., Praet, J. V., Farina, F., Davila-Valls, J., Martin-Perez, S., Ali, N. (2024). Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: Results from the EPICOVIDEHA Registry. Haematologica.
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_pathol_microbiol/1512